Get the Stockscreener App
5.55
3.65%
-0.21
Sage Therapeutics Inc Stock (SAGE) Latest News
Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - MM+M Online
Sage Therapeutics announces board member retirement By Investing.com - Investing.com Nigeria
Sage Therapeutics announces board member retirement - Investing.com India
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks By Investing.com - Investing.com South Africa
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Q1 Earnings Forecast for Sage Therapeutics Issued By Wedbush - MarketBeat
Sage Therapeutics to end development of key therapy after a third trial failure - MSN
Sage Therapeutics, Inc. Sued for Securities Law ViolationsCon - GuruFocus.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of "Hold" by Analysts - MarketBeat
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - MSN
Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com
Sage Therapeutics price target lowered to $4 from $7 at BofA - Yahoo Finance
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
RBC Capital Upgrades Sage Therapeutics (SAGE) - MSN
Sage raised to sector perform by RBC in wake of drug failure - MSN
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
Sage Therapeutics (NASDAQ:SAGE) Upgraded to "Sector Perform" at Royal Bank of Canada - MarketBeat
Sage scraps dalzanemdor after disappointing trial results - The Pharma Letter
Sage Therapeutics' Experimental Drug for Huntington's Disease Fails Mid-Stage Trial - Medical Dialogues
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder - AOL
Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s - Citeline
Third trial failure is end-of-the-road for Sage's neurological drug - The Business Journals
Sage to abandon development of neurological disorder drug after multiple failures - Reuters.com
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics - Benzinga
Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Sage slips as Huntington’s Disease therapy fails in mid-stage trial - Seeking Alpha
Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again - MarketWatch
Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - XM
Sage Therapeutics to end Huntington’s disease trial after drug fails again - MarketWatch
Sage Therapeutics' rare disease drug fails mid-stage study - XM
Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial | SAGE Stock News - StockTitan
Sage Therapeutics' stock falls after therapy fails for a third time - MarketWatch
CNS Drug Development: Same As It Ever Was (SAGE) - Seeking Alpha
BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com
FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com
Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Acumen Pharma Taps Former Sage Executive to Lead Alzheimer's Drug Development | ABOS Stock News - StockTitan
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com
Objective long/short (SAGE) Report - Stock Traders Daily
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):